Morgan Stanley highlights six Chinese medical device firms, projecting varied Q1 2026 sales growth amid US‑China tensions and supply disruptions.
Mindray expects low‑single‑digit sales rise and single‑digit profit decline; Shanghai United Imaging forecasts high‑teens sales growth and high‑single‑digit profit increase.
APT Medical targets ~30% sales surge; Shenzhen New Industries sees flat China sales with ~10% overseas growth; Imeik faces margin pressure and delayed product launch.
Analysts cite overseas expansion, product innovation, and macro‑geopolitical headwinds as key drivers for the sector’s sequential recovery.